

70591 U.S. PTO  
07/02/97

#19 7.31.97  
Bray

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Roeske, Roger W.

Serial No.: 08/480,494

Filed: June 7, 1995

For: *LHRH Antagonist Peptides*

Attorney Docket No.: PPI-007

Group Art Unit: 1811


Examiner: M. Borin

Assistant Commissioner for Patents  
Washington, D.C. 20231

"Express Mail" mailing label number EM303411224US

Date of Deposit July 2, 1997

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Assistant Commissioner for Patents, Washington, DC 20231

  
Flickie Cordoso  
Signature

TRANSMITTAL LETTER FOR DISKETTE OF SEQUENCE LISTING

Dear Sir:

Applicant submits herewith a diskette that contains a computer readable form of the Sequence Listing for the above-referenced application. The Sequence Listing complies with the requirements of 37 C.F.R. § 1.821-1.825. The material on this diskette is identical in substance to the Substitute Sequence Listing, which is submitted by

Preliminary Amendment on even date herewith. The computer readable form of the Sequence Listing contained on the enclosed diskette is understood to comply with the requirements of § 1.824(d). No new matter has been added.

Respectfully submitted,

  
Catherine J. Kara.  
Registration No. P41,106  
Agent for Applicants

LAHIVE & COCKFIELD, LLP  
60 State Street  
Boston, MA 02109  
Tel. (617) 227-7400

Dated: July 2, 1997

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: The sequence listing presented provides the sequense (SEQ ID #1) for the natural LHRH only. The sequence listings for the majority of claimed compounds, subject to Sequence Rules, have not been submitted. Peptides consisting entirely of four or more L-amino acids, whether naturally occurring or not, are subject to the rules. The non-naturally occurring amino acids are represented as Xaa in the Sequence Listing. All amino acid sequences recited in either the specification or the drawings must be followed by a SEQ ID NO. See 37 CFR 1.821(d). With respect to the use of the SEQ ID NOs in the claims, the examiner recommends that the SEQ ID NOs be placed inside of the semicolons immediately following the amino acid sequences. Should this application issue as a patent, there is no guarantee that the printer will print the claims in a format having only one sequence per line, and if the sequences are not so printed it will appear as though the SEQ ID NOs correspond to the following sequences.

Applicant must provide a substitute computer readable form (CRF) copy of the Sequence Listing, a substitute paper copy of the Sequence Listing as well as an amendment directing its entry into the specification, and a statement that the content of the paper and computer readable copies are the same and include no new matter as required by 37 CFR 1.825(a) and (b).

**Applicant Must Provide:**

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**